<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>364</td>
<td>Screening for scoliosis - New recommendations, old dilemmas, no straight solutions</td>
<td>Płaszewski M, Grantham W, Jespersen E</td>
</tr>
<tr>
<td>391</td>
<td>Effect of weekend admission on geriatric hip fractures</td>
<td>Pasternack JB, Ciminero ML, Silver M, Chang J, Simon RJ, Kang KK</td>
</tr>
<tr>
<td>400</td>
<td>Factors predisposing to thrombosis after major joint arthroplasty</td>
<td>Dailiana ZH, Stefanou N, Varitimids S, Rigopoulos N, Dimitroulias A, Karachalios T, Malizos KN, Kyriakou D, Kollia P</td>
</tr>
<tr>
<td>411</td>
<td>Supernumerary brachioradialis - Anatomical variation with magnetic resonance imaging findings: A case report</td>
<td>Kravarski M, Goerres GW, Antoniadis A, Guenkel S</td>
</tr>
</tbody>
</table>
ABOUT COVER

Editorial board member of World Journal of Orthopedics, Dr. Antonio Luna is a scientific director of the private diagnostic group HTmedica in Spain, where he began work as an attending physician in the body imaging section in 2000. Having received his MD degree from Granada University in 1994, he went on to obtain his PhD degree in 2016 from Malaga University. He also worked as an associate professor of radiology in the Radiology Department of University Hospital in Cleveland (Ohio, United States) from 2012 to 2019. Throughout his career, Dr. Luna’s research has focused on the clinical introduction of advanced MRI sequences, particularly in the fields of cardiac and oncological imaging. He has authored more than 60 peer-reviewed papers and 30 book chapters, and served as editor of 14 radiology books, lecturer in more than 100 medical meetings and reviewer for several Q1 journals of the specialty. (L-Editor: Filipodia)

AIMS AND SCOPE

The primary aim of World Journal of Orthopedics (WJO, World J Orthop) is to provide scholars and readers from various fields of orthopedics with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJO mainly publishes articles reporting research results and findings obtained in the field of orthopedics and covering a wide range of topics including arthroscopy, bone trauma, bone tumors, hand and foot surgery, joint surgery, orthopedic trauma, osteoarthropathy, osteoporosis, pediatric orthopedics, spinal diseases, spine surgery, and sports medicine.

INDEXING/ABSTRACTING

The WJO is now abstracted and indexed in PubMed, PubMed Central, Emerging Sources Citation Index (Web of Science), Scopus, China National Knowledge Infrastructure (CNKI), China Science and Technology Journal Database (CSTJ), and Superstar Journals Database.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Yan-Xia Xing Production Department Director: Xiang Li, Editorial Office Director: Jia-Ping Yan.

NAME OF JOURNAL

World Journal of Orthopedics

ISSN

ISSN 2218-5836 (online)

LAUNCH DATE

November 18, 2010

FREQUENCY

Monthly

EDITORS-IN-CHIEF

Massimiliano Leigheb

EDITORIAL BOARD MEMBERS

http://www.wjgnet.com/2218-5836/editorialboard.htm

PUBLICATION DATE

September 18, 2020

COPYRIGHT

© 2020 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

https://www.wjgnet.com/bpg/gerinfo/204

GUIDELINES FOR ETHICS DOCUMENTS

https://www.wjgnet.com/bpg/GerInfo/287

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

https://www.wjgnet.com/bpg/gerinfo/240

PUBLICATION ETHICS

https://www.wjgnet.com/bpg/GerInfo/288

PUBLICATION MISCONDUCT

https://www.wjgnet.com/bpg/gerinfo/208

ARTICLE PROCESSING CHARGE

https://www.wjgnet.com/bpg/gerinfo/242

STEPS FOR SUBMITTING MANUSCRIPTS

https://www.wjgnet.com/bpg/GerInfo/239

ONLINE SUBMISSION

https://www.ftpublishing.com

© 2020 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
E-mail: bpgoffice@wjgnet.com https://www.wjgnet.com
Screening for scoliosis - New recommendations, old dilemmas, no straight solutions

Maciej Płaszewski, Weronika Grantham, Ejgil Jespersen

ORCID number: Maciej Płaszewski 0000-0001-9874-5964; Weronika Grantham 0000-0001-7018-3023; Ejgil Jespersen 0000-0003-4512-4886.

Author contributions: Płaszewski M conceptualized the review, with substantial contributions from Grantham W and Jespersen E. He carried out the analysis and drafted the manuscript; Grantham W and Jespersen E made critical revisions related to important intellectual content of the manuscript. All authors reviewed and approved the final manuscript as submitted.

Conflict-of-interest statement: The authors declare no conflict of interests.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Abstract

This opinion review considers the prevailing question of whether to screen or not to screen for adolescent idiopathic scoliosis. New and improved standards of people-oriented care and person-centredness, as well as improved principles of preventive screening and guideline development, have been postulated and implemented in health care systems and cultures. Recommendations addressing screening for scoliosis differ substantially, in terms of their content, standards of development and screening principles. Some countries have discontinued issuing recommendations. In the last decade, a number of updated and new recommendations and statements have been released. Systematically developed guidelines and recommendations are confronted by consensus and opinion-based statements. The dilemmas and discrepancies prevail. The arguments concentrate on the issues of the need for early detection through screening in terms of the effectiveness of early treatment, on costs and cost-effectiveness issues, scientific and epidemiologic value of screenings, and the credibility of the sources of evidence. The problem matter is of global scale and applies to millions of people. It regards clinical and methodological dilemmas, but also the matter of vulnerable and fragile time of adolescence and, more generally, children’s rights. The decisions need to integrate people’s values and preferences – screening tests need to be acceptable to the population, and treatments need to be acceptable for patients. Therefore we present one more crucial, but underrepresented in the discussion, issue of understanding and implementation of the contemporary principles of person-centred care, standards of preventive screening, and guideline development, in the context of screening for scoliosis.

Key Words: Scoliosis; Screening; Tests; Programs; Recommendations; Guidelines; Principles; Benefits; Harms; Trustworthiness
INTRODUCTION

In this opinion review we will contribute to the discussion related to the prevailing question whether “to screen or not to screen for adolescent idiopathic scoliosis”[1-4]. We discuss the process of screening for scoliosis as it can be perceived today. Specifically, we present a crucial, but understated, issue of understanding and implementation of the contemporary principles of person-centred care, standards of preventive screening, and guideline development, in the context of screening for scoliosis.

On one hand, new and improved standards of people-oriented care and person-centredness have been postulated and implemented in health care systems and cultures[5-7]. New and improved principles of preventive screening[8,9] and guideline trustworthiness[10,11] have been introduced. On the other hand, health care systems and societies face dangers of distrust in evidence-based medicine[12-14] and unnecessary treatment[15-17], as well as of distrust in evidence-based medicine[12-14] and of disease mongering[15,16,18].

School screening for scoliosis was introduced in the United States in the 1960s[19]. The earliest, as it is called today, evidence-based recommendations on population screening, were released in Canada in 1979[20,21]. Since then, different guidelines, policies and statements were produced worldwide[22-24].

In the last decade, in the new era of guideline development[25-27,28], and after screening principles have evolved significantly[24,29,30], a number of updated and new recommendations and statements on screening for scoliosis[31-35], as well as on periodic examination of the spine[29], have been released. Nonetheless, the dilemmas prevail[36-38] and consensus does not seem to be reached[39,40]. Internationally, recommendations differ substantially, not only in terms of their content, but also standards of development and screening principles. Some countries have discontinued issuing recommendations addressing screening for scoliosis[24,25]. The evidence base for recommendation formulation is surprisingly limited[25,26,41-44]. The variations continue (Table 1)[45-49].

In the United Kingdom, screening for scoliosis is not recommended since the 1980s[40]. The United Kingdom National Screening Committee consequently recommends against screening[25,32], based on their set of principles, introduced in the early 2000s[41]. The Canadian Preventive Task Force on Preventive Health Care have not released any recommendation update since their 1994 recommendation against screening for scoliosis[24,25,46]. The Australian National Health and Medical Research Council, also operating on the basis of their advanced standards of guideline development[47], have archived their latest (2002) recommendations against screening[48] and do not continue releasing any new recommendations. The United States Preventive Services Task Force (USPSTF), have changed their recommendation from “no recommendation” in the 1990s[24,25], through a 2004 recommendation against screening[24,25] and, most recently, to a statement of insufficient evidence to formulate any recommendations[49]. Their key “I” recommendations are reported to the United States Congress[16,49]. Orthopaedic and rehabilitation organisations tend to support screening[24,25,46] (Table 1).

Consequently, the state of affairs in the United States remains peculiar. American
Table 1 Major current and historical recommendations about screening for scoliosis

<table>
<thead>
<tr>
<th>Institution, yr</th>
<th>Recommendation</th>
<th>Standard of development</th>
<th>Characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td>United States Preventive Services Task Force, 2018&lt;sup&gt;43&lt;/sup&gt;</td>
<td>No recommendation&lt;sup&gt;1&lt;/sup&gt; suggestion for practice: &quot;(…) if the service is offered, patients should understand the uncertainty about the balance of benefits and harms&quot;</td>
<td>Systematically developed; Screening programme criteria-based</td>
<td>Methods and standards following the USPSTF Procedure Manual; Systematic review addressing six key questions; Previous recommendation (2004): Against screening</td>
</tr>
<tr>
<td>AAP Bright Futures Guidelines, 2017/2019&lt;sup&gt;36&lt;/sup&gt;</td>
<td>Recommended (examination of the back)</td>
<td>Endorsement of the SRS/AAOS/POSNA/AAP 2015 position (below)</td>
<td>Examinations for scoliosis and &quot;other abnormalities&quot; during all (11-21 yr) Adolescence Health Supervision Visits</td>
</tr>
<tr>
<td>SOSORT, 2016 (published 2018)&lt;sup&gt;39&lt;/sup&gt;</td>
<td>Recommended (school screening programmes)</td>
<td>Consensus-based</td>
<td>Delphi method; Panel of experts and scoliosis conservative treatment practitioners; 2007 SOSORT screening consensus paper&lt;sup&gt;41&lt;/sup&gt; recommended as &quot;a reference for specific insights&quot;</td>
</tr>
<tr>
<td>United Kingdom National Screening Committee, 2010&lt;sup&gt;33&lt;/sup&gt;</td>
<td>Not recommended (national population-based screening programme)</td>
<td>Systematically developed; United Kingdom National Security Council (2015) screening programme criteria-based</td>
<td>Based on systematic evidence review&lt;sup&gt;40&lt;/sup&gt;, Criteria addressing the condition, the test, the intervention in terms of a clinically, socially and ethically acceptable screening programme: Recommendation sustained (2006, 2012)</td>
</tr>
<tr>
<td>SRS/AAOS/POSNA/AAP, 2015&lt;sup&gt;46&lt;/sup&gt;</td>
<td>Recommended (to be conducted in a medical home setting)</td>
<td>Opinion-based; narrative, including information on new evidence</td>
<td>Readers encouraged &quot;to reach their own decisions&quot; as the statement is not based on a systematic review; position confirmed&lt;sup&gt;41&lt;/sup&gt; after the USPSTF 2018 recommendation</td>
</tr>
<tr>
<td>SRS International Task Force, 2013&lt;sup&gt;34&lt;/sup&gt;</td>
<td>Recommended (school screening)</td>
<td>Consensus-based; research synthesis-guided</td>
<td>Expert consensus (Delphi method, seven surgeons, epidemiologist) on test technical efficacy, clinical, program, treatment, and cost effectiveness, using a dedicated systematic review&lt;sup&gt;41&lt;/sup&gt; and other available critical literature reviews</td>
</tr>
<tr>
<td>Historical (and discontinued) recommendations:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>National Health and Medical Research Council, Australia, 2002&lt;sup&gt;45&lt;/sup&gt;</td>
<td>Not recommended (rescinded guideline, not updated, archived)&lt;sup&gt;46&lt;/sup&gt;</td>
<td>Systematically developed</td>
<td>Based on critical review against criteria of screening tests characteristics, treatment effectiveness, burden of suffering; No current guidelines or guidelines in development</td>
</tr>
<tr>
<td>Canadian Task Force on Preventive Health Care, 1994&lt;sup&gt;40&lt;/sup&gt;</td>
<td>No recommendation: insufficient evidence to recommend for or against (historical guideline, not updated)&lt;sup&gt;46&lt;/sup&gt;</td>
<td>Systematically developed</td>
<td>Based on critical review of the evidence of benefits and harms of screening and treatment; No current guidelines or guidelines in development</td>
</tr>
</tbody>
</table>

<sup>1</sup>The current evidence is insufficient to assess the balance of benefits and harms of the service. Evidence is lacking, of poor quality, or conflicting, and the balance of benefits and harms cannot be determined<sup>41</sup>.

<sup>2</sup>For more details see Table 8.


The arguments concentrate on the issues of the need for early detection through screening, the effectiveness of early (conservative, especially bracing) treatment, and consequent reduced surgery rate<sup>40,43,60,61</sup>, on costs of screening procedures and cost-effectiveness of screening programmes<sup>40,41,60,61</sup>, as well as on scientific and epidemiologic value of screenings<sup>40,41,60,61</sup> and the credibility of the sources of evidence<sup>40,41,60,61</sup>. Nonetheless, systematically developed guidelines and recommendations are confronted by consensus and opinion based statements (Table 1).

The trust in expert opinions, rather than in systematically developed guidelines and recommendations, seems to be related to the scepticism, or unfamiliarity with the principles of evidence-based practice, and about the importance of its implementation<sup>40,43</sup>. In our view, however, it is also a matter of understanding and implementation of the contemporary principles and standards of screening (while both issues are very much related). We propose a discussion around screening for scoliosis put in this context.
The problem matter is of global scale, applies to millions of people, and screening programmes have usually been school-based. It regards clinical and methodological dilemmas, but also the matter of vulnerable and fragile time of adolescence and, more generally, the matter of preserving children’s rights. The decisions need to integrate people’s values and preferences – screening tests need to be acceptable to the population, and treatments need to be acceptable for patients.

**PEOPLE-CENTRED CARE**

The World Health Organisation’s Global Strategy of Integrated People-centred Health Services 2016–2026 underpins that people and communities need to be placed at the centre of health services, with terms and actions such as people-centred care, person-centred care and engagement, representing this philosophy.

Shared decision making is the core of people-centred care. Decisions need to be grounded in patients’ values and perspectives, as engaging patients in making choices and decisions leads to better health outcomes and better healthcare experiences. Standardised information, such as patient decision aids, are replacing traditional educational and information tools, as the way clinicians provide information may strongly affect people’s preferences. We summarise those key terms in Table 2.

**GUIDELINE DEVELOPMENT AND RECOMMENDATION FORMULATION TODAY**

Standards of guideline development and recommendation formulation have been improved in recent years (Table 3). Based on the Institute of Medicine standards of guideline development, guidelines not based on systematic review of the evidence were no longer included in the National Guideline Clearinghouse database.

Contemporary sets of criteria for trustworthy guidelines do not duplicate, but control for conflicts of interests, multidisciplinary guideline development group composition, public engagement, shared decision making and respecting people’s voices are their common features. Interestingly, these have been postulated by the Evidence-Based Medicine Working Group specifically addressing guidelines and recommendations about screening as early as in 1999 (Table 4).

**EVOLUTION OF SCREENING PRINCIPLES**

The 1968 World Health Organisation’s “Principles and Practice of Screening for Disease” (Table 5) have become the gold standard, and are still used as a frame of reference.

Nonetheless, the understanding, principles, and criteria of screening have evolved over the years, and numerous proposals and policies have been formulated and introduced. A recent synthesis study located 41 sets of standards and 367 screening principles (Table 6).

In contrast with the Wilson and Jungner’s “screening for disease” (Table 5), defining screening as secondary prevention (early disease detection), contemporarily screening is defined as preventive service, covering all stages of management, from prevention, through diagnostics, to treatment (Table 6).

Harris et al. propose to introduce the term “predictor of poor health” to emphasize a focus on health outcomes. The terminology shifted from “asymptomatic subjects” to “otherwise healthy individuals” (“It is sometimes useful, we think, to use a term that refers to all forms of early detection whether by screening, physical examination or other means; and this is meant when we use the term “early disease detection,” “The purpose of screening is to improve the length and/or quality of people’s lives, not just to find abnormalities”).

Importantly, however, Wilson and Jungner postulated that both the treatment and the test need to be acceptable to the population, and that the first aim is to avoid harms to the patients. The underpinning principle is that screening may be beneficial, but it can also be harmful (“In adhering to the principle of avoiding harm to the patient...”)

---

**References**

Table 2 Terms related to people-centred care and person-centred care

<table>
<thead>
<tr>
<th>Terms</th>
<th>People-centred care</th>
<th>Person-centred care</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>“Organised around the health needs and expectations of people rather than diseases (…) requires that people have the education and support they need to make decisions and participate in their own care”[5]; “extends the concept of patient-centred care to individuals, families, communities and society”[6]</td>
<td>“Care approaches that see the person as a whole with many levels of needs and goals, with these needs coming from their own personal and social determinants of health”[5]</td>
</tr>
<tr>
<td>Engagement</td>
<td>“Involving people and communities in the design, planning and delivery of health services that (…) enable them to make choices about care and treatment options”[5]</td>
<td></td>
</tr>
<tr>
<td>Patient decision aids</td>
<td>“Evidence-based tools designed to help patients specific and deliberated choices among health-care options”[5]</td>
<td></td>
</tr>
<tr>
<td>Shared decision-making</td>
<td>“Process through which clinicians and patients make health care choices together”[5]</td>
<td></td>
</tr>
</tbody>
</table>

Table 3 Generic standards of trustworthiness for guidelines and recommendations

|---------------------------------|--------------------------------------------|

Table 4 Screening-addressed standards of trustworthiness for guidelines and recommendations

<table>
<thead>
<tr>
<th>“How to use guidelines and recommendations about screening”, Evidence-Based Medicine Working Group, 1999[28]</th>
</tr>
</thead>
<tbody>
<tr>
<td>“Are the recommendations valid?</td>
</tr>
<tr>
<td>Is there randomized controlled trial evidence that earlier intervention works?</td>
</tr>
<tr>
<td>Were the data identified, selected and combined in an unbiased fashion?</td>
</tr>
<tr>
<td>What are the recommendations and will they help you in caring for your patients?</td>
</tr>
<tr>
<td>What are the benefits?</td>
</tr>
<tr>
<td>What are the harms?</td>
</tr>
<tr>
<td>How do these compare in different people and with different screening strategies?</td>
</tr>
<tr>
<td>What is the impact of people’s values and preferences?</td>
</tr>
<tr>
<td>What is the impact of uncertainty?</td>
</tr>
<tr>
<td>What is the cost-effectiveness?”</td>
</tr>
</tbody>
</table>

at all costs (the primum non nocere of Hippocrates), treatment must be the first aim”[29].

HARMS OF SCREENING

Problems of potential harms of screening, such as overdiagnosis and unnecessary treatment, have gained much attention recently[14-17]. These concerns correspond with the debate on widening the definitions of diseases, narrowing the definition of health, with medicalisation of unpleasant experiences of everyday life[17,18], and presenting presymptomatic, early or minor problems as serious conditions[17,18,22]. Another potential driving factor for overdiagnosis and unnecessary treatment is using a common term – label of a single “disease” – for a heterogeneity of conditions of wide spectrum of health outcomes[17,18,22-25], and the phenomena of “apparent illness”[25], attributed to overdetection due to increased testing and improved diagnostic tools,
Table 5 Wilson and Jungner screening principles, World Health Organization 1968[29]

<table>
<thead>
<tr>
<th>1</th>
<th>The condition sought should be an important health problem</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>The natural history of the condition, including development from latent to declared disease, should be adequately understood</td>
</tr>
<tr>
<td>3</td>
<td>There should be a recognizable latent or early symptomatic stage</td>
</tr>
<tr>
<td>4</td>
<td>There should be a suitable test or examination</td>
</tr>
<tr>
<td>5</td>
<td>The test should be acceptable to the population</td>
</tr>
<tr>
<td>6</td>
<td>There should be an agreed policy on whom to treat as patients</td>
</tr>
<tr>
<td>7</td>
<td>There should be an accepted treatment for patients with recognized disease</td>
</tr>
<tr>
<td>8</td>
<td>Facilities for diagnosis and treatment should be available</td>
</tr>
<tr>
<td>9</td>
<td>The cost of case-finding (including diagnosis and treatment of patients diagnosed) should be economically balanced in relation to possible expenditure on medical care as a whole</td>
</tr>
<tr>
<td>10</td>
<td>Case-finding should be a continuing process and not a “once and for all” project</td>
</tr>
</tbody>
</table>

WHO: World Health Organization.

Calls for renaming low risk conditions labelled as cancers[30] and the “tripling of the incidence of thyroid cancer, with unchanged death rate”[17], are striking examples, but analogies to adolescent idiopathic scoliosis, both in terms of the progression of the condition, as well as severity and a very wide spectrum of potential health outcomes, are also noticeable. In Table 7, we summarise the drivers of “too much medicine”[14,17,29,77] and present our view of corresponding issues regarding screening for scoliosis.

Screening programmes are recognised as justified when they address conditions which would lead to earlier death or significant decline in health if a condition is not detected through screening[14,17,29,77]. A proposed screening programme need to be evaluated against evidence on the magnitude of health benefits, but also against the evidence on the magnitude of health harms. The factors on the harms side of the screening balance are the frequency of false-positive tests, the frequency of overdiagnosis, and the experience of overdiagnosed people (Table 7)[29,30], considered in relation to the magnitude (frequency and severity) of harm[1,8,9,14,17,18,77].

Harms are no longer understood purely in terms of direct adverse events or side effects of diagnostic testing (such as x-ray exposure[26,43]) and of treatment (such as skin irritation by a brace[82]). They are meant as the value of health lost due to the overdiagnosed or false-positive health state, such as anxiety and complications of labelling, diagnostics, unneeded or unnecessary treatment, and stigmatisation[14,17,29,30,77].

“The experience of overdiagnosis (…) often life-changing, (…) includes unnecessary psychological and physical effects from labelling, diagnostic evaluation, and treatment, (…) is itself associated with harm”[8].

**UPDATED RECOMMENDATIONS, OUTDATED STANDARDS?**

Disputes over screening for scoliosis have focused on the condition-specific arguments, such as the need for early detection and treatment, and the evidence for the effectiveness of nonsurgical treatment, in terms of avoiding the need for surgery. Less attention is paid to the dispute regarding the evolving generic concepts, standards and principles of screening.

**People-centredness**

Decisions about treatment (and screening) options are considered “preference-sensitive” because of insufficient evidence about the outcomes and because a trade-off between known benefits and harms is needed[29]. Individual people do not necessarily benefit from treatments, even if they show beneficial effects for populations[14,17]. People differ in their judgements of the balance of potential harms and benefits of
Table 6 Fifty years after Wilson and Jungner, Consolidated principles for screening, 2018

"Consolidated principles for screening" Dobrow et al, 2018

<table>
<thead>
<tr>
<th>&quot;Disease/condition principles:</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Epidemiology of the disease or condition (...) should be adequately understood, and the disease or condition should be an important health problem</td>
</tr>
<tr>
<td>2 Natural history of disease or condition (...) should be adequately understood, the disease or condition is well-defined, and there should be a detectable preclinical phase</td>
</tr>
<tr>
<td>3 Target population for screening (...) should be clearly defined (e.g., with an appropriate target age range), identifiable and able to be reached</td>
</tr>
</tbody>
</table>

Test/ intervention principles:

| 4 Screening test performance characteristics (...) should be appropriate for the purpose, with all key components specific to the test (...) being accurate (...) and reliable or reproducible. The test should be acceptable to the target population and it should be possible to perform or administer it safely, affordably and efficiently |
| 5 Interpretation of screening test results. Screening test results should be clearly interpretable and determinate (e.g., with known distribution of test values and well-defined and agreed cut-off points) to allow identification of the screening participants who should (and should not) be offered diagnostic testing and other postscreening care |
| 6 Postscreening test options. There should be an agreed (...) course of action for screening participants with positive screening test results that involves diagnostic testing, treatment or intervention, and follow-up care that will modify the natural history and clinical pathway for the disease or condition; that is available, accessible and acceptable to those affected; and that results in improved outcomes (...). The burden of testing on all participants should be understood and acceptable, and the effect of false-positive and false-negative tests should be minimal |

Program/ system principles:

| 7 Screening program infrastructure (…) |
| 8 Screening program coordination and integration (…) |
| 9 Screening program acceptability and ethics. All components of the screening program2 should be clinically, socially and ethically acceptable to screening participants, health professionals and society, and there should be effective methods for providing screening participants with informed choice, promoting their autonomy and protecting their rights |
| 10 Screening program benefits and harms. The expected range and magnitude of benefits (…) and harms (…) for screening participants and society should be clearly defined and acceptable, and supported by existing high-quality scientific evidence (or addressed by ongoing studies) that indicates that the overall benefit of the screening program outweighs its potential harms |
| 11 Economic evaluation of screening program (…) (e.g., cost-effectiveness analysis, cost-benefit analysis and cost-utility analysis) (…), using a health system or societal perspective, (…) to assess the full costs and effects of implementing, operating and sustaining the screening program while clearly considering the opportunity costs and effect of allocating resources to other potential nonscreening alternatives (…) |
| 12 Screening program quality and performance management (…) |

1based on a systematic review and a modified Delphi consensus process, using 41 sets and 367 screening principles9; elaborations abridged;

2i.e. “recruitment, testing, information access, diagnosis, referral, treatment, follow-up, patient education and support, staff training and program management and evaluation”9.

screening. Hence they need to be informed and participate in decision making9,10. It is considered an ethical duty to encourage people to decide for themselves9. The 2017 Cochrane review on patient decision aids (an update of the most cited Cochrane review in 2014)9 included studies involving adults making decisions for themselves, for a child or for a significant other, about screening or treatment options. None of the 105 included trials, and none of the excluded studies, addressed scoliosis. None of the discussed guidelines and position statements (Table 1 and Table 8) invited screening
Table 7 “Drivers of overdiagnosis” and their relation to scoliosis screening

<table>
<thead>
<tr>
<th>Category</th>
<th>Factor</th>
<th>Examples of disputable and unclear scoliosis issues</th>
</tr>
</thead>
<tbody>
<tr>
<td>Broadening disease definitions</td>
<td>Lowering of diagnostic thresholds</td>
<td>Cut-off point of 10° Cobb; treatment starts from 20°-25° Cobb[36,37]; proposed 6° Cobb cut-off point[26]</td>
</tr>
<tr>
<td>Technology</td>
<td>Use of advanced technology for diagnosis</td>
<td>Mild scoliosis with no symptoms, disputable risk of progression; inconclusive/unconvincing evidence for treatment effectiveness</td>
</tr>
<tr>
<td>Technology</td>
<td>Use of more sensitive screening tests</td>
<td>Proposals of advanced imaging technologies[29,30] and follow-up tests connected to potential overdiagnosis</td>
</tr>
<tr>
<td>Public health interventions</td>
<td>Widespread screening</td>
<td>Screening programmes mainly school-based[26,31,32]; millions of adolescents subjected to school screening[59,60,61]</td>
</tr>
<tr>
<td>Culture of medical care</td>
<td>Value of diagnosis for its own sake</td>
<td>Testing encouraged by professional organisations[33,34,35,36]</td>
</tr>
<tr>
<td>Clinician cognitive errors</td>
<td>Overestimation of benefit of therapy in mild or low risk disease</td>
<td>Evidence-to-practice gaps as regards effectiveness of early conservative treatment[25,26,37] and differences in long term health outcomes between treated and untreated people[38-40]</td>
</tr>
<tr>
<td>System factors</td>
<td>Financial incentives for more testing</td>
<td>-</td>
</tr>
<tr>
<td>Evidence limitations</td>
<td>Lack of clarity regarding disease spectrum in studies of diagnostic accuracy</td>
<td>Disputable AIS severity divisions (mild–moderate–severe) vs broad and unspecified curve spectrums (e.g. 10°-50° Cobb) and screening test accuracy[26,30]</td>
</tr>
</tbody>
</table>

AIS: Adolescent idiopathic scoliosis.

participants or included an analysis of their voices. The SRS/AAOS/American Academy of Pediatrics (AAP)/POSNA[16,18] or Scientific Society on Scoliosis Orthopaedic and Rehabilitation Treatment[8] statements do not contain any information on patients’ engagement or shared decision making. Five, out of ten, Wilson and Jungner[9] principles, considered by the SRS International Task Force[5,12], were technical efficacy, clinical effectiveness, program effectiveness, treatment effectiveness, and cost-effectiveness. The United Kingdom National Security Council formulated their recommendations based on eleven criteria[26], and the USPSTF on eight “key questions”[26] (Table 8), none of them include such issues.

One present day phenomenon, of importance regarding sources of information and evidence, but also particularly about people-centredness, is the digital revolution. The access to health information has democratised, people are using new technologies to share information and experiences, build social networks and run blogs[26]. Social networks are becoming sources of scientific evidence[34] and websites, blogs and social media are today recognised as grey literature[35]. These apply for people with scoliosis, and for scoliosis research and practice[36].

The child perspective

The problem of screening for scoliosis is about adolescents and their school environment. In 2017, seven out of eight international screening programmes were school-based[26].

According to the United Nations Convention on the Rights of the Child, children have, among other rights, the right to “express an opinion, and to have that opinion taken into account, to privacy, to protection from abuse or neglect”[26]. In concert with this, the recent “Unique Needs of the Adolescents” Policy Statement of the AAP, calls for protecting the rights of adolescents through developmentally appropriate, adolescent-centred, family-involved care, addressing physical and mental health, confidentiality, socioeconomic factors, and sexual and gender development, in terms of identity, relationships and roles[26], (“In adolescents to whom confidentiality is not assured, there is a higher prevalence of depressive symptoms, suicidal thoughts, and suicide attempts”[26]).

The AAP’s Bright Future guidelines for health supervision were updated in 2017 and 2019 with a “new focus on social determinants of health and on lifelong physical and mental health”[36]. Nonetheless, as of scoliosis, the guidelines simply refer to the 2015 position of the orthopaedic societies[26].
Table 8 Unmet and partially met United States Preventive Services Task Force[26] and United Kingdom National Screening Committee[43] key questions and criteria, tested in recommendation formulation on screening for scoliosis

<table>
<thead>
<tr>
<th>Criterion</th>
<th>Findings/conclusions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Key Questions, United States Preventive Services Task Force, 2018[26].</td>
<td>No relevant RCTs or CCTs, evaluating the impact of screening on curve severity or adult health outcomes</td>
</tr>
<tr>
<td>Does screening improve: (1) Health AIS outcomes, and (2) The degree of abnormal spinal curvature in childhood or adulthood?</td>
<td>No studies directly addressing this question: none of two included studies reported health outcomes data stratified by curve degree at skeletal maturity</td>
</tr>
<tr>
<td>What is the association between severity of spinal curvature in adolescence and health outcomes in adulthood?</td>
<td>No studies met inclusion criteria</td>
</tr>
<tr>
<td>What are the harms of screening for AIS?</td>
<td>Harms of bracing reported in one good-quality study[81] (relatively benign skin problems and nonback pain; one out of 146 participants hospitalised due to anxiety and depression); no other studies or evidence on other harms</td>
</tr>
<tr>
<td>What are the harms of treatment of AIS that has a Cobb angle of less than 50° at diagnosis?</td>
<td>Not met; Poor PPV of FBT test in distinguishing whether treatment or observation is needed; potential overdetection, waste of resources and unnecessary x-ray exposure</td>
</tr>
<tr>
<td>Screening criteria¹, United Kingdom National Screening Committee, 2016[43].</td>
<td>Partially met; No single established cut-off value; other uncertainties, including additional use of Moiré topography and optimal screening age</td>
</tr>
<tr>
<td>There should be a simple, safe, precise and validated screening test</td>
<td>Not met; Two studies were eligible, but were conducted in clinically detected cases, and did not compare treatment after screen detection and after clinical detection; no evidence found on effectiveness of conservative treatments of mild scoliosis and on surgical treatment outcomes in screen-detected vs clinically detected severe cases</td>
</tr>
<tr>
<td>The distribution of test values in the target population should be known and a suitable cut-off level defined and agreed</td>
<td>Partially met; Specific Cobb angle cut-off for observation or treatment introduction, or a particular treatment approach, difficult to identify</td>
</tr>
<tr>
<td>There should be an effective treatment or intervention for patients identified through early detection, with evidence of early treatment leading to better outcomes than late treatment</td>
<td>Not met; Adherence to bracing prescribed following screen detection difficult to define/recognise; no studies on adherence to other conservative treatments or on uptake following recommendation for surgery</td>
</tr>
<tr>
<td>There should be agreed evidence based policies covering which individuals should be offered treatment and the appropriate treatment to be offered</td>
<td>Not met; Specific Cobb angle cut-off for observation or treatment introduction, or a particular treatment approach, difficult to identify</td>
</tr>
<tr>
<td>There should be evidence that the complete screening programme (test, diagnostic procedures, treatment/ intervention) is clinically, socially and ethically acceptable to health professionals and the public</td>
<td>Not met; Adherence to bracing prescribed following screen detection difficult to define/recognise; no studies on adherence to other conservative treatments or on uptake following recommendation for surgery</td>
</tr>
</tbody>
</table>

¹There are 20 United Kingdom National Screening Committee screening criteria, addressing the condition, the test, the intervention, the programme, and implementation criteria; the table includes criteria categorised as "unmet" or "partially met" in the Screening for adolescent idiopathic scoliosis: external review against programme appraisal criteria for the United Kingdom National Screening Committee[43]. AIS: Adolescent idiopathic scoliosis; RCT: Randomised controlled trial; CCT: Clinical controlled trial; FBT: Forward bend test.

Evidence base and standards of recommendation formulation

The SRS/AAOS/AAP/POSNA in their 2015 statement[33,46] urged the USPSTF to update their recommendations in view of new evidence of brace treatment effectiveness[82]. The conclusions of the USPSTF are, in fact, opposite. They formulated their “I” statement that “(…) the current evidence is insufficient to assess the balance of benefits and harms of the service. Evidence is lacking, of poor quality, or conflicting, and the balance of benefits and harms cannot be determined”[34,74] (Table 1). USPSTF follows rigorous guideline development standards and procedures[74,75]. In contrast,
their previous (2004) recommendation was based on a “brief evidence update”[9] of low methodological quality, lacking expected reporting of the search, selection, and appraisal of the evidence[9].

Importantly, both the USPSTF[8], and the United Kingdom National Security Council[8] systematic reviews, produced in the preparation of recommendation formulation (Table 1), did not find convincing evidence for a number of criteria and key questions, including harms of screening, long term treatment effects, and differences in health outcomes between screen- and clinically detected cases, as well as whether they may be associated with the condition, the treatment (including screening and workup) or the diagnosis (Table 5).

Expert opinions are contemporarily not considered as a substitute for evidence in guideline development standards and methods[10,11,26]. Systematically developed guidelines – both current and historical (Table 1) – are, to a different extent, sceptical about school screening for scoliosis[12,13,14,15]. Nonetheless, the distrust[16] and opposite claims[17,18] continue.

**Continuum of disease definition – mild scoliosis**

The minimum criterion for diagnosis of scoliosis, the cut-off point of 10° in the Cobb classification[19,20,21], is questioned[22,23] as “based on convention”[24]. Brace treatment starts from 20-25° Cobb[26,27,28,29], so there is a gap between a diagnosed condition and a condition with available (effective) treatment[26,27,30] – one of the principles of a justified screening programme[31,32,33,34] (Tables 4-6). Additionally, for the majority of screen-positive persons, adolescent idiopathic scoliosis will be a benign condition – curves progress among about two-thirds of adolescents, but only one-third and less than 10% of the diagnosed will experience progression of more than 10° and 30°, respectively[35,36]. In the screening programmes, the majority of detected curves were 10°-19°, thus only the minority will progress to the 20°-25° threshold for brace treatment[37,38,39]. And only very few will progress to more severe deformities, which may require surgery (prevalence of 0.1% in adolescents and of 0.4% in general population for curves exceeding 40°)[40,41]. Furthermore, the false-positive rates for the routinely used, and recommended, forward bend test, are up to 21.5%[42]. The critiques of population-based screening argue that deformities requiring treatment will be diagnosed clinically, even in the absence of screening programmes (Table 1). “Distribution of curves was similar for children detected through school-based screening compared to those who were detected clinically”[40,41]. And the effectiveness of school screening on curve magnitude at clinical presentation, in comparison to clinically detected cases, is reported as doubtful[42].

**Aesthetics and body acceptance are potential challenges in people with scoliosis:**

Labelling mild “deviations” from “norms” need to be considered in this context[44,45,46]. The connection with scoliosis, body image and mental health issues are well recognised in research, but in people with diagnosed, typically serious, deformities, and who are treated for scoliosis[47,48,49,50]. Not in “otherwise asymptomatic” (i.e healthy) young people referred to screening. “Adolescent idiopathic scoliosis is most often asymptomatic during adolescence, and is (...) not typically associated with clinical finding other than body asymmetry”[12].

The evidence is unconvincing whether slowing down the curve progression has other positive health outcomes in body function and person-oriented outcomes such as pain, psychosocial status, and body experience. On the other hand, aesthetics is considered an important criterion of treatment[46]. Mild scoliosis may be recognised as a health condition, as it is considered in both the prevailing societal stereotypes and biomedically (rather than psychosocially) oriented assumptions of straight (perfect) bodies[48,49,50,51] (Figure 1).

The literal meaning of “orthopaedics” is “straight child, free from deformity”, and it comes from the XVIII century[52].

**CONCLUSION**

Opinion-based health care recommendations and guidelines tend to be no longer valid. Evidence-base, and strength of the recommendations, are followed, or at least addressed, in contemporary guidelines, recommendations and position statements on screening for scoliosis. Nonetheless, trustworthiness of individual documents remains disputable. Problems include formulating conclusions based on selective citations rather than on research syntheses, with emphasis on potential benefits of treatment,
and silence on systematically developed recommendations against screening, or the fact that scoliosis screening has been discontinued in countries with established standards of guideline development and implementation.

Guidelines, recommendations and position statements are even more discrepant, when taking into consideration contemporary principles and standards of screening. These apply especially to experiences of people and potential personal harms, including those following over-detection and false-positive test findings, labelling, overtreatment, and stigmatisation. There is no consideration of the issues of informed choice and shared decision making. Knowledge translation tools, educational materials or patient decision aids are not considered in any of those documents.

Nonetheless, the discussed documents have at least one crucial commonality. The SRS/AAOS/POSNA/AAP 2015 position\cite{33,46} includes a significant recommendation that “screening exams for spine deformity should be part of medical home preventive services”. The “Unique Needs of the Adolescents” statement promotes the Patient-Centred Medical Homes\cite{64}. Bright future guidelines recommend spine examination during individual Adolescent Periodic Health Visits\cite{36}.

Potentially, this could be a more respectful way of examining the spine than the school-based procedure. It does make a difference in terms of person-centredness, whole-person orientation and, more broadly, schools as “safe places”\cite{64}. Perhaps medical homes could be the right places to examine for scoliosis in adolescent- and family-oriented, respectful way, in confidentiality, by properly trained personnel, not only in terms of the accuracy of testing but also in terms of ensuring the unique needs of adolescents. As regards to screening programmes, potential harms to all screened adolescents, not only to those diagnosed, as well as shared decision-making, need to be considered.

Furthermore, all of these are recommendations for spine examinations rather than screening programmes.

It is important to stress that the idea of this paper is to highlight the issue of screening understood as a preventive programme, rather than as a test\cite{1,8,9,29,30} or a clinical back inspection, especially in order to underline the important and underrepresented in the literature issues of people-centredness and shared decision-making. Standards such as the Bright Future guidelines\cite{36}, and reports on the necessity for accessible primary care for adolescents, including careful spine examinations\cite{106}, are unquestionable.

Nonetheless, there are still many debatable issues related to this subject matter, such as delivering services and ensuring person-centeredness in areas where health visits are not mandatory or not provided. One of the aims of this opinion review is an invitation for further discussion regarding this multidimensional subject matter.

In terms of preventive screening, an answer to the question on how to screen for scoliosis, instead of whether to screen (“to screen or not to screen for scoliosis”), is warranted.
REFERENCES


8  Harris R, Sawaya GF, Moyer VA, Calonge N. Reconsidering the criteria for evaluating proposed screening programs: reflections from 4 current and former members of the U.S. Preventive services task force. Epidemiol Rev 2011; 33: 20-35 [PMID: 21666224 DOI: 10.1093/epirev/mxr005]


Płaszewski M, Bettany-Saltikov J. Are current scoliosis school screening recommendations evidence-based and up to date? A best evidence synthesis umbrella review. *Eur Spine J* 2014; 23: 2572-2585 [PMID: 24777669 DOI: 10.1007/s00586-014-3207-z]


Fong DYT, Luk KDK. Should screening for scoliosis be conducted? *Arthroscopy* 2012; 4: 46-49 [DOI: 10.1242/ijh.12400.012.0040-3]


UK National Screening Committee. Screening for adolescent idiopathic scoliosis: external review against programme appraisal criteria for the UK National Screening Committee (UK NSC) 3rd ed. London: UK National Screening Committee, 2015


Kale MS, Korenstein D. Overdiagnosis in primary care: framing the problem and finding solutions. BMJ 2018; 362: k2820 [PMID: 30108054 DOI: 10.1136/bmj.k2820]
Screening for scoliosis and principles of screening

Płaszewski M et al. WJO 2020; 11(9): 78-80


